Printer Friendly

FUJISAWA USA UNIFIES SALES AND MARKETING OPERATIONS

 DEERFIELD, Ill., Sept. 8 /PRNewswire/ -- Fujisawa USA, Inc., today announced the integration of its two sales and marketing operations. The former Fujisawa Pharmaceutical Company and Lyphomed sales forces, and their respective internal marketing departments, have been restructured with a customer focus, replacing the traditional product orientation. This will allow customers to see one sales representative for all their multisource and proprietary product needs. Patrick D. Walsh, vice president of sales and marketing, will lead the new organization.
 "This unification represents another step in our strategic plan to prepare our company for changes in the American pharmaceutical marketplace," said Hatsuo Aoki, chairman and CEO of Fujisawa USA. "We want to provide our customers with the business expertise integral to providing quality care in a cost effective manner."
 Walsh added, "Our customers' needs in light of the evolving healthcare industry were the impetus to changing the structure of our sales force. We are establishing a sales and marketing team that can address the business and clinical needs that our customers face each day."
 Fujisawa USA, Inc., headquartered in Deerfield, is a manufacturer of proprietary and multisource pharmaceutical products and a subsidiary of Fujisawa Pharmaceutical Co., Ltd., based in Osaka, Japan.
 -0- 9/8/93
 /CONTACT: Paula Waters, 312-329-7532, or Angela Chaplin, 312-329-7672, both for Fujisawa, USA/


CO: Fujisawa USA, Inc.; Fujisawa Pharmaceutical Co., Ltd. ST: Illinois IN: MTC SU: PER

LG -- NY063 -- 9870 09/08/93 13:34 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 8, 1993
Words:237
Previous Article:QUAKER INCREASES QUARTERLY DIVIDEND PAYOUT BY 10.4 PERCENT
Next Article:FUJISAWA USA APPOINTS HERRICK TO MARKET PLANNING POST
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters